F.I.B

Question 1

Bispecific antibodies

Answer 1

Off-the-shelf given intravenously
Molecular rope (antibody) tethered her natural t-cells to the tumor cells
Can be made produced in advance
Can be good for blood and lymph cancers

Might work equally well in (myeloma-blood cancer)
Challenging to design and produce-however now faster, more potent and safer

Often does not give the same omg. Lasting remissions as CAR T

Not that good with solid tumors (colon & lungs(

Question 2

CAR T cells

Answer 2

Chimeric antigen receptor t-cells
Harvesting patients blood, engineering them to have receptors for tumor antigen, growing more, infusing back in

Takes too long, has to be prepared for each cancer patient

Altered to carry a receptor that targets a cancer cell antigen

Question 3

Antibodies

Answer 3

Y showed proteins, binding takes place at tips of Y
Can directly disable, and clear a pathogen or can signal immune response to it

Modular, w/ two identical heavy chains(stem/half of each arm), 2 identical light chain(each completed one arm)

Pathogen fighters, latch onto antigen on viruses bacteria, microbes

Question 4

Monoclonal antibodies

Answer 4

Trastuzumab/herceptin–(breast cancer drug)

Question 5

Checkpoint inhibitor

Answer 5

Drugs that release the molecular brakes that can restrain T cells, can also boos the T cells attack

Question 6

T cell CD3 protein

Answer 6

If this is used the all T cells can engage directly attack not just the trained ones

Question 7

Cytokine storms

Answer 7

Immune overreaction in which white blood cells pump out signals called cytokines that can be toxic in large quantities

Can be caused by both CAR T and bispecifics

Question 8

BiTE

Answer 8

Bispecific T cell engager
Pump
Stripped down bispecific antibody with two tips linked by a flexible peptide instead of traditional stem
Similar to CAR T- release toxic molecules and performs that punch holes in tumor cells and cause self destruct